THROMBOTIC EFFECTS OF ASPARAGINASE IN TWO ACUTE LYMPHOBLASTIC LEUKEMIA PROTOCOLS (NOPHO ALL-1992 VERSUS NOPHO ALL-2000): A Single-Institution Study

REFERENCES

• Kidd J G. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum—course of transplanted cancers of various kinds in mice and rats given guinea pig serum or rabbit serum. J Exp Med. 1953; 98: 565–582, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Broome J D. Evidence that the L-asparaginaseof guinea pig serum is responsible for its antilymphoma effects and properties of the L-asparaginase of guinea pig serum and yeast in relation to those of the the antilymphoma substance. J Exp Med. 1963; 118: 99–120, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Müller H J, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998; 28: 97–113, [CSA]
   PubMed Web of Science ®Google Scholar
• Priest J R, Ramsay N K, Steinherz P G, et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982; 100: 984–989, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Priest J R, Ramsay N K, Bennett A J, Krivit W, Edson J R. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia. J Pediatr. 1982; 100: 990–995, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Andrew M, Monagle P T, Brooker L. Thromboemblic Complications During Infancy and Childhood. BC Decker, Hamilton, London 2000
   Google Scholar
• Ruud E, Holmstrom H, Natvig S, Wesenberg F. Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer: a prospective study. Med Pediatr Oncol. 2002; 38: 405–410, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Gatta G, Corazziari I, Magnani C, Peris-Bonet R, Roazzi P, Stiller C. Childhood cancer survival in Europe. Ann Oncol 2003; 14(Suppl 5)v119–v127, [PUBMED], [CROSSREF], [CSA]
   Google Scholar
• Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia 2000; 14: 2267–2275, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pinheiro J P, Boos J. The best way to use asparaginase in childhood acute lymphatic leukaemia—still to be defined? [Review] [69 refs]. Br J Haematol. 2004; 125: 117–127, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Albertsen B K, Schroder H, Jakobsen P, Muller H J, Carlsen N T, Schmiegelow K. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clini Pharmacol. 2001; 52: 433–437, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996; 32A: 1544–1550, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Asselin B L. The three asparaginases: comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999; 457: 621–629, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Eden O B, Shaw M P, Lilleyman J S, Richards S. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol. 1990; 18: 497–502, [PUBMED], [CSA]
   PubMedGoogle Scholar
• Alberts S R, Bretscher M, Wiltsie J C, O'Neill B P, Mokri B, Witzig T E. Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Leuk Lymphoma. 1999; 32: 489–496, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res. 2001; 103: 165–172, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mitchell L, Hoogendoorn H, Giles A R, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. Blood. 1994; 83: 386–391, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Werber G, Ziemann D, Ahlke E, Boos J. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL. Haematologica. 1996; 81: 127–131, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• De Cicco M, Matovic M, Balestreri L, et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 1997; 86: 101–113, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003; 21: 3665–3675, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. [Review] [82 refs]. Blood Coagul Fibrinolysis 1994; 5(Suppl)36, [CSA]
   Google Scholar
• Nowak-Gottl U, Boos J, Wolff J E, et al. Asparaginase decreases clotting factors in vitro: a possible pitfall?. Int J Clini Lab Res 1995; 25: 146–148, [CSA]
   PubMedGoogle Scholar
• Mitchell L G, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 2003; 97: 508–516, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hak L J, Relling M V, Cheng C, et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 2004; 18: 1072–1077, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Ahlke E, Schulze-Westhoff P, Boos J. Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation. Br J Haematol 1996; 95: 123–126, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Nowak-Gottl U, Rath B, Binder M, et al. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. [Comment]. Haematologica. 1995; 80: 451–453, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia: results of the PARKAA study. Thromb Haemost 2003; 90: 235–244, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Male C, Chait P, Ginsberg J, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children. Thromb Haemost. 2002; 87: 593–598, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar